CER Daily Newsfeed

Emory Using Real-World Evidence for Medication Formulary Design

(3/26, David Raths, Healthcare Innovation) reports “Atlanta-based Emory Healthcare is in the early stages of partnering with Stanford Medicine spinout Atropos Health on real-world evidence generation. The Atropos Evidence Network, with over 300 million patient records, is working with Emory users to run studies on both large national data sets and local Emory data. Emory’s Collin Lee, PharmD, director of clinical pharmacy services, recently spoke with Healthcare Innovation about some use cases around medication formulary design and protocols.” Full

Oz Open To Considering March-In Rights, Vague On IRA Issues

(3/25, Maaisha Osman, Inside Health Policy) reports “...In his written response to Senate Finance Committee questions March 17, Oz signaled a willingness to address pharmacy concerns over Medicare's drug price negotiations but avoided taking a firm stance on key policies. Asked whether he would intervene in CMS' implementation of the Inflation Reduction Act (IRA), Oz echoed the Trump administration's commitment to lowering drug costs but did not commit to specific actions.” Subscription Required

 A Plea From Seniors: Eliminate the Biden Pill Penalty

(3/25, Jim McLaughlin, RealClearHealth) comments “...Eighty-six percent of voters aged 55 and older fear that the Biden Pill Penalty will slash investment in small molecule drug R&D, limiting future treatment options. Eighty-seven percent worry that these medicines will be harder to obtain, forcing reliance on more expensive, less effective alternatives. Additionally, eighty-two percent support passing the EPIC Act to eliminate the Biden Pill Penalty.” Full

Senate Confirms Johns Hopkins Surgeon Marty Makary to Lead FDA Amid Turbulence at the Agency

(3/26, Fraiser Kansteiner, Fierce Pharma) reports “...As for other issues raised during the hearing, Makary expressed his desire to review the FDA’s independent advisory committees more broadly to avoid possible conflicts of interest, as well as to potentially accelerate the approval pathway for generic and biosimilar drugs.” Full